|
|
Original Research Article
Association of Fibroblast
Growth Factor (Fgf-21) as a Screening Biomarker for
Chronic Progressive External Ophthalmoplesia
Farnaz Farzaneh Dehkordi1*,
Massoud Houshmand2,
Majid Sadeghizadeh3,
Mohsen Bahmani Kashkouli4 and Gholamreza
Javadi1
1Biology Department, Science
and Research Branch, Islamic Azad University, 2Medical
Genetics Department, National Institute of Genetic
Engineering and Biotechnology, 3Department of
Genetics, Faculty of Biological Sciences, Tarbiat
Modares University, 4Iran University of
Medical Sciences, Tehran, Iran.
*For correspondence:
Email:
farzaneh_farnaz2007@yahoo.com;
Tel: +98-9127336690
Received: 15 December 2013
Revised accepted: 19
January
2014
Tropical Journal of
Pharmaceutical Research, March 2014;
13(3):
377-381
http://dx.doi.org/10.4314/tjpr.v13i3.10
Abstract
Purpose:
To
investigate whether or not fibroblast growth factor (FGF-21)
can be used as a screening biomarker in chronic
progressive external ophthalmoplesia (CPEO) patients.
Methods: FGF-21 concentration was measured
in the serum of 24 patients with CEPO phenotype and 24
control samples by enzyme-linked immunosorbent assay
(ELISA) and determined the deletion of mitochondrial
genome by multiplex polymerase chain reaction (PCR).
Results: FGF-21 concentration in 50 % of CPEO
patients showed notable differences from that in control
subjects. FGF-21 concentration ratio in patient group, 2
disorder control groups (mitochondrial and
non-mitochondrial) and normal group,
respectively, was 294.87 ± 42.10 (p < 0.0001),
761.78± 75.07 (p < 0.0001), 124.26 ± 12.27 (p = 0.1203),
69.27 ± 10.09 (p = 0.2195). A statistically significant
inverse correlation between FGF-21 concentration and age
onset was found, with a significant difference (p <
0.05) in the age group ≤ 19 years (mean FGF-21
concentration, 460.36 pg/mL) and for the age group ≥
51years
(mean
concentration FGF-21, 57.87 pg/mL. Surprisingly, there
was no significant difference between FGF-21
concentration and age in the mid-age group (20 – 50
years) .
Conclusion: These findings indicate that FGF-21
concentration significantly increases in CPEO patients
like in other mitochondrial disorders and this factor
can be used as a biomarker in primary diagnosis of
mitochondrial disorders. In this regard, FGF-21 assay is
only valid in teenagers and the > 50 years age group who
show acute symptoms.
Keywords: Chronic progressive
external ophthalmoplesia, Fibroblast growth factor-21,
Mitochondrial disorders, Ophthalmoplesia, Biomarker. |
